<DOC>
	<DOCNO>NCT01549548</DOCNO>
	<brief_summary>The main purpose protocol provide expand access study drug ( Ponatinib/AP24534 ) people imatinib- , dasatinib- , nilotinib- resistant/intolerant Philadelphia Chromosome Positive ( Ph+ ) Leukemias . The purpose protocol monitor safety study drug people Ph+ Leukemias respond prior treatment .</brief_summary>
	<brief_title>Compassionate Use Ponatinib</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Ponatinib</mesh_term>
	<criteria>Signed date informed consent Cytogenetic PCRbased diagnosis phase Ph+ acute lymphoblastic leukemia ( ALL ) document resistance intolerance imatinib second TKI ( nilotinib , dasatinib , bosutinib ) Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Washout prior antiproliferative antileukemia treatment : 3 day hydroxyurea/anagrelide tyrosine kinase inhibitor &lt; Grade 2 baseline recovery prior therapy related toxicity ( except alopecia ) At least 3 month post allogeneic stem cell transplantation Able take oral capsule reliably AST/ALT le equal 2.5 time ULN , less 5 time ULN attributable involvement leukemia No active clinical radiographic pancreatitis At least 18 year age Willingness male female subject use reliable method birth control ( applicable ) Subjects Philadelphia Chromosome BCRABLnegative chronic myeloid leukemia ( CML ) Major surgery radiotherapy within 7 day first dose Ponatinib ( recovery previous surgery complete day 1 ) Clinically significant active/uncompensated uncontrolled cardiac disease ( active congestive heart failure ; uncontrolled angina hypertension ; myocardial infarction past 3 month ; clinically significant untreated ventricular arrhythmia ; diagnose suspect congenital acquire prolonged QT syndrome ; unexplained syncope ; history prolong QTc ) Prolonged QTc ( &gt; 0.48 sec ) Pregnant breastfeed woman Evidence serious active infection , significant medical psychiatric illness Known seropositivity HIV , current acute chronic Hepatitis B Hepatitis C ( antigen positive ) , cirrhosis , clinically significant abnormal lab find would , investigator 's judgment , make subject inappropriate study Prior resistance Ponatinib</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>CML</keyword>
</DOC>